Platelet activation contributes to graft occlusion after bypass surgery. This study investigated platelet activation status before, during, and after bypass. Blood was taken preoperatively from patients undergoing femoro-popliteal bypass and at incision, after dissection, after ischemia, after reperfusion, 24 hours after surgery, and almost 2 years after bypass (and given aspirin or warfarin). Platelet aggregation was measured using a turbidimetric method and platelet activation with flow cytometry. Statistical analysis was performed using Mann-Whitney U and Wilcoxon's tests. Resting platelet activation was similar between controls and patients undergoing bypass. Platelet activation decreased at incision but remained highly reactive. Platelet aggregation increased after dissection and the ischemic phase but significantly decreased after reperfusion. Platelet aggregation and activation were increased at 24 hours and subsequently after bypass. Platelets in critical limb ischemia exist in the primed state and become activated by minimum stimuli. Increased platelet activation occurs after bypass grafting for critical limb ischemia despite adjunctive therapy.
Collins TC, Souchek J., Beyth RJBenefits of antithrombotic therapy after infrainguinal bypass grafting: a meta-analysis. Am J Med.2004;117:93-99.
3.
Barradas MA, Stansby G., Hamilton G., Mikhailidis DPDiminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol.1994;13:202-207.
4.
Walters TK, Mitchell DC, Wood RFLow-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg.1993;80:1266-1268.
5.
Trifiletti A. , Barbera N., Pizzoleo MA, et al. Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. J Cardiovasc Surg (Torino). 1995; 36: 483-485.
6.
Sixma JJInteraction of blood platelets with the vessel wall. In: Bloom AL, Forbes CD, Thomas DF, Tuddenham EGD , eds. Haemostasis and Thrombosis. 3rd ed. Edinburgh: Churchill Livingstone;1994:259-285.
7.
Cheshire Njw , Wolfe Jhn, Barradas MA, Chambler AW, Mikhailidis DPSmoking and plasma fibrinogen, lipoprotein (a), and serotonin are markers for postoperative infrainguinal graft stenosis . Eur J Vasc Endovasc Surg.1996;11:479-486.
8.
Robless PA, Okonko D., Lintott P., Mansfield AO, Mikhailidis DP, Stansby GPIncreased platelet aggregation and activation in peripheral arterial disease . Eur J Vasc Endovasc Surg.2003;25:16-22.
9.
Michelson AD , Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A.1996 ;93:11877-11882.
10.
McBane RD II , Karnicki K., Tahirkheli N., Miller RS, Owen WGThe impact of peripheral arterial disease on circulating platelets. Thromb Res.2004 ;113:137-145.
11.
Antiplatelet Trialists' Collaboration.Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J.1994;308: 81-106.
12.
Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ.2002;324:71-86.
13.
Jagroop IA, Matsagas MI, Geroulakos G., Mikhailidis DPThe effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets.2004;15:117-125.
14.
Dutch BoaTrial Participants. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet. 2000;355:346-351.
15.
Michelson AD , Furman MILaboratory markers of platelet activation and their clinical significance. Curr Opin Hematol.1999;6:342-348.
16.
Abrams C., Shattil SJImmunological detection of activated platelets in clinical disorders. Thromb andHaemost. 1991;65:467-473.
17.
Barradas MA , O'Donoghue S., Jagroop A., Mikhailidid DPLaboratory techniques in drug development (2): advantages of whole blood platelet aggregation measured by a cell counter (Coulter T-890) in drug evaluation. J Drug Dev.1992;5:155-166.
18.
Tsakiris DA , Tschopl M., Wolf F., et al. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis. 2000;11:165-173.
19.
McBane RD II , Karnicki K., Tahirkheli N., Miller RS, Owen WGPlatelet characteristics associated with coronary artery disease. J Thromb Haemost.2003;1:1296-1303.
20.
Labios M., Martinez M., Gabriel F., Guiral V., Martinez E., Aznar J.Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thromb Res.2005;115:263-270.
21.
Holme PA, Orvim U., Hamers MJ, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol. 1997;17:646-653.
22.
Fuster V., Badimon L., Badimon JJ, Chesebro JHThe pathogenesis of coronary artery disease and the acute coronary syndromes . N Engl J Med.1992;326:242-250.
23.
Sakariassen KS, Örning L., Stormorken H.Role of ADP and thromboxanes in human thrombus formation in ex vivo models. Platelets.1997 ;8:385-390.
24.
Robless P., Mikhailidis DP, Stansby G.Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg.2001;88:787-800.
25.
Schneider DJ , Tracy PB, Mann KG, Sobel BEDifferential effects of anticoagulants on the activation of platelets ex-vivo. Circulation. 1997;96:2877-2883.
26.
Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L., Wakeling A., Dandona P.Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest.1985;15:313-319.
27.
Legrand C., Morandi V., Mendelovitz S., Shaken H., Hartman JR, Panet A.Selective inhibition of platelet macroaggregate formation by a recombinant heparin-binding domain of human thrombospondin. Arterioscler Thromb. 1994; 14:1784-1791.
28.
Viscentin GP, Ford SE, Scott JP, Aster RHAntibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest.1994;93:81-88.
29.
Schroder K.The basic pharmacology of ticlopidine and clopidogrel. Platelets.1992;4:252-261.
30.
Mastagas M., Jagroop IA, Geroulakos G., Mikhailidis DPThe effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost. 2003;9:115-120.
31.
, Joseph JE, Machin SJNew antiplatelet drugs. Blood Rev.1997;11:178-190.
32.
Allie DE, Hebert CJ, Lirtzman MD, et al. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. J Invasive Cardiol. 2005;17:427-432.
